Sign in to view content

APX3330, an Oral Drug in Trial for DR and DME, Demonstrated a Favorable Safety and Tolerability Profile in Multiple Phase 1 and 2 Studies

Michael J Allingham, MD, PhD

Video
Published 2021

Related

Impact of PRAME Status on Gene Expression Profile to Predict Metastasis in Uveal Melanoma: Interim Analysis of the Collaborative Ocular Oncology Group Study Number 2 (COOG2)
Prithvi Mruthyunjaya, MD, MHS
Updates from the Field
2022
Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss
Jennifer K. Sun, MD
Updates from the Field
2019
Assessment of the Inclusion of Racial/Ethnic Minorities in Retina Clinical Trials
Vivienne S. Hau, MD, PhD
Updates from the Field
2022

Category: Diabetic Retinopathy

See more